Oak Therapeutics, based in Oxnard, announced that it completed a study of the use of its dissolvable strips to administer an anti-tuberculosis treatment orally.
A 300 milligram dose of isoniazid on the dissolvable strips given to canines entered the bloodstream at a statistically similar rate to commercial tablets, the study found.
The company, a subsidiary of Oxnard-based Cure Pharmaceutical, called the study a “critical milestone” in a contract with the National Institutes of Health and National Institute of Allergy and Infectious Diseases.
“We have now successfully established the technical merit, feasibility and commercial potential for the reformulation of (isoniazid) as an ODS,” Oak Therapeutics President Edward Maliski said in a news release. “As a result, Oak has been invited to submit a proposal for Phase II of this project, bringing us one step closer to commercializing an ODS treatment option for TB.”
The product could be used for the delivery of antibiotics and pain relievers in the future, Maliski said, with the goal of helping patients adhere to dosing schedules.
• Contact Marissa Nall at [email protected]